  
|
|
 |  |  |  |  |  |  |  |
Editorial: Autism and Prenatal SSRI Exposure - Examining the Link
Submitting your vote...
Every few months, it seems as if still another study appears in the literature linking fetal exposure to selective serotonin reuptake inhibitors (SSRIs) with an adverse outcome, such as increased risk for a particular congenital malformation or some other ill effect. Despite many studies that have examined a potential association between risk for malformations and prenatal SSRI exposure, a major indication that an agent is a teratogen is consistency of the finding across studies, which has not been the case with SSRIs.
On the other hand, studies indicating that babies whose mothers use SSRIs during pregnancy might have symptoms of transient jitteriness for a period following birth (neonatal adaptation syndrome) have been more consistent – and this is generally accepted as a real risk following approximately 20%-25% of deliveries. Other major concerns raised about fetal exposure to SSRIs have not been supported by systematic scientific investigation.
|
By Dr. Lee Cohen |
Clinicians may then wonder why we are seeing an increasing number of reports of potential adverse outcomes associated with SSRI treatment during pregnancy. One reason is that technology has afforded us the ability to gather information from large administrative databases (such as Medicaid or large health maintenance organizations) about prescriptions written during pregnancy and a variety of obstetrical and neonatal outcomes data. Conclusions about a teratogenic outcome or adverse perinatal outcome are only as reliable as the quality of the data from which the conclusions are derived and, unfortunately, some of the data from these databases have been profoundly lacking.
In still another study using such data, published online in Archives of General Psychiatry in July, investigators from Kaiser Permanente Northern California reported an association between an increased risk for autism spectrum disorders (ASDs) in children and maternal SSRI use during pregnancy (Arch. Gen. Psychiatry 2011 [doi:10.1001/archgenpsychiatry.2011.73]).
The population-based case-control study used medical records of 298 children diagnosed with an ASD (autism, Asperger’s syndrome, or pervasive developmental disorder not otherwise specified) and 1,507 children without an ASD diagnosis born within the Kaiser Permanente system in northern California between 1995 and 1999. The results suggested a greater risk of an ASD among children exposed to an SSRI in utero, compared with nonexposed children: The mothers of 6.7% of children with ASD (20 children) had been prescribed at least one antidepressant (mostly SSRIs) during the year before the child was born, compared with the mothers of 3.3 % of controls (50 children).
After a purported adjustment for maternal age and other possible confounding factors, maternal use of an SSRI during the year before delivery was associated with a twofold increased risk of an ASD; treatment during the first trimester was associated with almost a fourfold increased risk. Among the children whose mothers had a history of mental health treatment but did not take SSRIs, the risk of ASD was not increased.
Neurology RSS
Interested in being notified of new Neurology news?
Click here to view our Neurology RSS Feed.
| May 24 - 27 Chicago, IL | Association for Psychological Science (APS): Annual Convention |
| May 29 - Jun 1 Phoenix, AZ | National Institute of Mental Health (NIMH): New Clinical Drug Evaluation Unit (NCDEU) |
| Jun 3 - 7 Stockholm, | Collegium Internationale Neuro-Psychopharmacologicum (CINP): World Congress |
| Jun 5 - 10 Kona, HI | International Behavioral Neuroscience Society (IBNS): Annual Meeting |
| Jun 12 - 17 Chicago, IL | American Psychoanalytic Association (APsaA): 101st Annual Meeting |
| Jun 18 - 26 Rapid City, SD | Reclaiming Youth International: 19th Annual Black Hills Seminars |
| Jun 23 - 27 San Francisco, CA | Research Society on Alcoholism (RSA): Annual Scientific Conference |
| Jul 10 - 13 Liverpool, | Royal College of Psychiatrists: Annual Meeting |
| Jul 21 - 28 Dpart Venice, | Primary Care: Mental Health Issues with a Focus on Drugs and Behavior |
| Jul 21 - 25 Paris, | International Association for Child & Adolescent Psych & Allied Professions (IACAPAP): World Congress |